Loading clinical trials...
Loading clinical trials...
Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)
Conditions
Interventions
Biospecimen Collection
Cisplatin
+8 more
Locations
123
United States
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California, United States
Los Angeles General Medical Center
Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Shaw Cancer Center
Edwards, Colorado, United States
Helen F Graham Cancer Center
Newark, Delaware, United States
Medical Oncology Hematology Consultants PA
Newark, Delaware, United States
Start Date
June 3, 2025
Primary Completion Date
February 1, 2032
Completion Date
February 1, 2032
Last Updated
April 15, 2026
NCT06173349
NCT06350734
NCT06766266
NCT04164082
NCT07064863
NCT04548193
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions